Authors: Tori B. Terrell-Hall, Mohamed Ismail Nounou, Fatema El-Amrawy, Jessica I.G. Griffith, and Paul R. Lockman
Source: oncotarget.com
Oncotarget. 2017; 8:83734-83744.
Received: March 15, 2017. Accepted: July 03, 2017. Published: July 26, 2017.
Synopsis: Drug and antibody delivery to brain metastases has been highly debated in the literature. The blood-tumor barrier (BTB) is more permeable than the blood-brain barrier (BBB), and has shown to have highly functioning efflux transporters and barrier properties, which limits delivery of targeted therapies.